The Clinical Trials Information Centre aims to give you information about what clinical trials are taking place that you may be eligible for. The search function below allows you to search by your location, your treatment stage and the stage of the trial. If you find a trial you think you may be eligible for, we suggest you print the information to take along to your next appointment with your clinical team as you will not be able to join the trial without the support of your clinical team.

In addition to the larger trials taking place in centres across the UK, there are sometimes phase I trials which have an even stricter entry criteria. We have not listed all of these but have instead listed where the phase I centres are so that you can ask your clinical team to contact them to find out if there’s any trials you may be eligible for.

This site will be updated regularly as trials are opening and closing in different locations all the time. Whilst we endeavour to keep it as up to date as we can, please always check with your clinical team about the availability of a trial in your area.

If you have any queries about the clinical trials information centre, you can call the Target Ovarian Cancer support line on 020 7923 5475 or email

Miles of

Results list

This trial is looking at whether the additional drug treatment of avelumab alongside platinum based chemotherapy improves progression free survival (the length of time during and after treatment that a woman lives with the disease but it does not get worse) in women with stage III / IV disease at diagnosis. It is a three arm trial:
Clear cell cancer is a rare type of cancer. If it starts in the ovary or the lining of the womb (endometrium), doctors often treat it with surgery followed by chemotherapy. But sometimes the cancer can continue to grow or come back after treatment. In this situation chemotherapy is not always helpful and so researchers are looking for new treatments. In this trial they are looking at a drug called nintedanib.
Trametinib is a drug that blocks a very important signal that controls the growth of cancer cells. It is thought that this signal is important in a variety of cancers, including low-grade serous ovarian and peritoneal cancers. Trametinib is experimental and has not yet been studied in patients with low-grade serous ovarian or peritoneal cancer. 
Surgery is the usual treatment for ovarian cancer. A CT scan is used to check where the cancer is in the body and helps doctors to know if surgery would be a suitable treatment choice.  However, sometimes the CT scan can’t:
Researchers are looking for new ways to treat people with advanced cancer that is getting worse despite treatment. In this trial, they are looking at LY2940680 and a chemotherapy drug called paclitaxel. LY2940680 is a type of biological therapy called a cancer growth blocker. It stops signals that cancer cells use to divide and grow. The aims of the trial are to find the highest safe dose of LY2940680 to give with paclitaxel and to learn more about the side effects.
Women will be randomised into two groups:                   Group B1 Women in this group will receive 18 weeks of: Carboplatin once every three weeks Paclitaxel once every three weeks Bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months Group B3 Women in this group will receive 18 weeks of:
The aims of the trial are to: find the highest safe dose of pazopanib and fosbretabulin when the two drugs are given together learn more about the side effects of the drugs see whether pazopanib and fosbretabulin together work better than pazopanib alone. The trial is in two parts. The first part of the trial is to work out the best dose of both drugs to give. This involves three – six participants receiving doses of both drugs that are believed to be safe.
The researchers need about 588 people to take part worldwide and hope that around 50 people from the UK will take part. This trial is randomised and the people taking part are put into one of two groups: carboplatin and pegylated liposomal doxorubicin trabectedin and pegylated liposomal doxorubicin Your group is decided by a computer and neither you nor your doctor will be able to decide which group you are. If you are in the carboplatin and pegylated liposomal doxorubicin group, you will have treatment every four weeks.
TroVax helps the immune system to recognise and attack cancer cells. The aim of this trial is to find out if giving TroVax after a rise in CA125 (but before symptoms return) can slow the growth of cancer and delay the start of chemotherapy.  Treatment lasts 11 months and this will include approximately 12 visits to hospital. 
Doctors usually treat ovarian cancer with surgery followed by chemotherapy. The chemotherapy often includes a platinum drug such as carboplatin. If your cancer gets worse within six months of having this treatment, it is called platinum resistant. You may then have treatment with a taxane chemotherapy drug called paclitaxel. But sometimes the cancer starts to grow again. So researchers are looking at ways to delay this. In this trial, they are looking at AZD2014. It is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.